» Articles » PMID: 22071120

Individual-level Syringe Coverage Among Needle and Syringe Program Attendees in Australia

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2011 Nov 11
PMID 22071120
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Harm associated with injecting drug use is a significant public health issue and a major cause of morbidity and mortality, with global estimates of 3 million injectors infected with HIV and 8 million living with chronic hepatitis C virus (HCV) infection. Estimates of program coverage are widely used in the context of HIV prevention and are critical in determining the effectiveness of interventions such as Needle and Syringe Programs (NSPs).

Methods: Data from a national cross-sectional study of NSP attendees in Australia were used to estimate individual-level syringe coverage as a proportion of monthly injections covered by a new syringe. Univariate and multivariate logistic regressions modelled associations between demographics, injecting risk, anti-HIV and HCV prevalence and syringe coverage. The median number of syringes retained per NSP attendee per annum was also estimated.

Results: Twenty percent of participants had insufficient new syringes for all injections. Syringe reuse (including reuse of one's own syringe) was independently associated with syringe coverage of <100%. Conversely, procurement of syringes from an NSP was independently associated with syringe coverage ≥100%, with a greater protective effect occurring when NSP utilisation was combined with current engagement in opiate substitution therapy. The median number of syringes retained per participant per annum was 720, equivalent to 2 per day.

Conclusions: While Australian NSP attendees report high syringe coverage by international standards, prevention efforts could be scaled up. Syringe reuse was associated with syringe coverage of <100%, suggesting the utility of reuse as a proxy for individual-level syringe coverage.

Citing Articles

Updates on syringe coverage and service uptake among needle and syringe programs in the United States, 2019-2020.

Tookes H, Bartholomew T, Soto Sugar S, Plesons M, Bluthenthal R, Wenger L Int J Drug Policy. 2023; 123:104289.

PMID: 38071932 PMC: 10878422. DOI: 10.1016/j.drugpo.2023.104289.


Prevalence and associates of non-fatal overdose among people who inject drugs in Saveh, Iran.

Armoon B, Griffiths M, Bayani A, Mohammadi R, Ahounbar E Addict Sci Clin Pract. 2022; 17(1):42.

PMID: 35927753 PMC: 9351099. DOI: 10.1186/s13722-022-00325-2.


Syringe Coverage Among People Who Inject Drugs in West Virginia, USA.

Allen S, White R, ORourke A, Schneider K, Weir B, Lucas G AIDS Behav. 2021; 25(10):3377-3385.

PMID: 33886011 DOI: 10.1007/s10461-021-03247-3.


Non -fatal overdose among people who inject drugs in Tehran, Iran.

Noroozi M, Higgs P, Bayani A, Armoon B, Nazeri Astaneh A, Fattah Moghaddam L Subst Abuse Treat Prev Policy. 2020; 15(1):80.

PMID: 33054806 PMC: 7559998. DOI: 10.1186/s13011-020-00323-0.


Measures of harm reduction service provision for people who inject drugs.

OKeefe D, Bluthenthal R, Kral A, Aitken C, McCormack A, Dietze P Bull World Health Organ. 2019; 97(9):605-611.

PMID: 31474773 PMC: 6705510. DOI: 10.2471/BLT.18.224089.